| Literature DB >> 33212902 |
KwangSun Do1,2,3, JongEun Yim1,3.
Abstract
Background: Functional limitations may still remain even after a patient completes a traditional quadriceps-based rehabilitative program after total knee arthroplasty. Based on studies reporting that patients with knee osteoarthritis have muscle weakness around the hip joint after total knee arthroplasty, we investigated whether strengthening the hip muscles can reduce pain and improve the physical function and gait of patients who underwent total knee arthroplasty.Entities:
Keywords: gait pattern; hip muscle exercise; physical function; quadriceps; total knee arthroplasty
Year: 2020 PMID: 33212902 PMCID: PMC7711674 DOI: 10.3390/healthcare8040489
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1Flow diagram of the experimental procedure.
Hip abductor and adductor muscle strengthening exercises.
| Exercise | Dosage |
|---|---|
| Warm up (AROM) | 10 min |
| Supine extension bridge with thera-band | 3 sets of 20 at a RPE 5~7 |
| Sideway walking with thera-band | 3 sets of 20 steps at a RPE 5~7 |
| Standing hip adduction with thera-band | 3 sets of 20 at a RPE 5~7 |
| Clamshell (Hip external rotation) with thera-band | 3 sets of 20 at a RPE 5~7 |
Quadriceps muscle strengthening exercises.
| Exercise | Dosage |
|---|---|
| Warm up (AROM) | 10 min |
| Seated knee extension with thera-band | 4 sets of 20 at a RPE 5~7 |
| Supine straight leg raise with thera-band | 4 sets of 20 at a RPE 5~7 |
| Quarter wall squat with thera-band | 4 sets of 20 at a RPE 5~7 |
General characteristics of participants (n = 55).
| Characteristic | All Patients | Hip Group | Quadriceps Group | Control Group | |
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
| Sex (Men/Women) | 8(16.4%)/47(83.6%) | 3(15.8%)/16(84.2%) | 3(15%)/17(85%) | 3(18.8%)/13(81.3%) | 0.952 |
| Age (years) | 72.80 ± 5.47 | 72.84 ± 7.03 | 72.50 ± 4.73 | 73.13 | 0.945 |
| Height (cm) | 154.76 ± 5.64 | 155.07 ± 5.86 | 154.28 ± 5.25 | 155.00 ± 6.17 | 0.894 |
| Weight (kg/m2) | 60.65 ± 5.00 | 60.58 ± 5.02 | 61.05 ± 5.50 | 60.25 ± 4.61 | 0.893 |
| BMI (kg/m2) | 37.47 ± 2.76 | 37.19 ± 2.59 | 37.60 ± 3.03 | 37.62 ± 2.75 | 0.868 |
SD, standard deviation; BMI, body mass index; ROM, range of motion; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Outcome scores for each group at baseline (week 0), post-intervention (week 4), follow-up (week 8), and follow-up 2 (week 12): mean and standard deviation.
| Outcome Measure | Hip Group | Quadriceps Group | Control | F |
| Post Hoc |
|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | ||||
| Flexion ROM | ||||||
| Baseline | 114.42 ± 10.52 | 115.15 ± 9.33 | 117 ± 5.79 | 0.378 | 0.687 | |
| 4 week f/w | 118.32 ± 9.39 | 120.4 ± 7.25 | 118.44 ± 5.66 | 5.8 | 0.005 * | B > C |
| 8 week f/w | 119.53 ± 9.19 | 121.45 ± 6.73 | 118.56 ± 5.64 | 9.274 | 0.001 * | A, B > C |
| 12 week f/w | 119.84 ± 8.82 | 122.7 ± 6.4 | 118.88 ± 5.62 | 11.006 | 0.001 * | A, B > C |
| Time × Group | 3.382 | 0.004 * | ||||
| Extension ROM | ||||||
| Baseline | 10.37 ± 5.6 | 8.1 ± 3.58 | 9.13 ± 3.09 | 1.371 | 0.263 | |
| 4 week f/w | 8.58 ± 4.76 | 6.8 ± 2.72 | 8.19 ± 2.56 | 1.509 | 0.231 | |
| 8 week f/w | 7.79 ± 4.41 | 6.2 ± 2.3 | 8 ± 2.65 | 4.776 | 0.013 * | A, B > C |
| 12 week f/w | 7.84 ± 4.11 | 6.1 ± 2.33 | 7.63 ± 2.6 | 2.604 | 0.084 | |
| Time × Group | 2.291 | 0.041 * | ||||
| WOMAC-P | ||||||
| Baseline | 12.32 ± 2.42 | 12.75 ± 2.78 | 12.19 ± 2.56 | 0.239 | 0.788 | |
| 4 week f/w | 8.21 ± 4.14 | 10.1 ± 2.97 | 11.25 ± 1.91 | 6.547 | 0.003 * | A > C |
| 8 week f/w | 8.37 ± 2.56 | 9.6 ± 2.41 | 11 ± 2.12 | 11.474 | 0.001 * | A, B > C |
| 12 week f/w | 8.05 ± 3.2 | 9.8 ± 2.39 | 10.69 ± 2.15 | 7.677 | 0.001 * | A > C |
| Time × Group | 3.493 | 0.004 * | ||||
| WOMAC-F | ||||||
| Baseline | 41.89 ± 5.36 | 45.1 ± 7.13 | 45.31 ± 4.78 | 1.931 | 0.155 | |
| 4 week f/w | 33.74 ± 8.93 | 38.2 ± 6.38 | 43.56 ± 3.75 | 8.464 | 0.001 * | A, B > C |
| 8 week f/w | 33.32 ± 8.49 | 37.35 ± 5.94 | 41.5 ± 4.32 | 5.767 | 0.006 * | A > C |
| 12 week f/w | 32.05 ± 8.76 | 36.75 ± 5.32 | 40.31 ± 4.84 | 5.499 | 0.007 * | A > C |
| Time × Group | 1.456 | 0.201 |
SD, standard deviation; ROM, range of motion; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index. * p < 0.05.
Outcome scores for each group at baseline (week 0), post-intervention (week 4), follow-up (week 8), and follow-up 2 (week 12): mean and standard deviation.
| Outcome Measure | Hip | Quadriceps | Control | F |
| Post Hoc |
|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | ||||
| AST | ||||||
| Baseline | 15.72 ± 3.98 | 16.13 ± 4.99 | 14.24 ± 3.18 | 0.977 | 0.383 | |
| 4 week f/w | 12.17 ± 2.66 | 14.26 ± 3.54 | 13.76 ± 2.85 | 7.684 | 0.001 * | A > B, C |
| 8 week f/w | 11.68 ± 3.3 | 14.31 ± 3.53 | 13.67 ± 2.51 | 10.470 | 0.001 * | A > B, C |
| 12 week f/w | 11.17 ± 2.69 | 14.46 ± 3.8 | 13.23 ± 2.6 | 13.336 | 0.001 * | A > B, C |
| Time × Group | 3.999 | 0.001 * | ||||
| FTSST | ||||||
| Baseline | 15.25 ± 3.16 | 16.25 ± 3.64 | 14.49 ± 2.8 | 1.326 | 0.274 | |
| 4 week f/w | 13.25 ± 2.6 | 13.12 ± 2.76 | 13.92 ± 2.29 | 13.595 | 0.001 * | A, B > C |
| 8 week f/w | 12.58 ± 2.58 | 12.77 ± 1.99 | 13.79 ± 2.01 | 11.074 | 0.001 * | A, B > C |
| 12 week f/w | 12.69 ± 2.7 | 13.26 ± 2.32 | 13.29 ± 1.97 | 4.09 | 0.022 * | A, B > C |
| Time × Group | 4.699 | 0.001 * | ||||
| TUG | ||||||
| Baseline | 14.19 ± 2.37 | 15.44 ± 3.13 | 15.38 ± 3.1 | 1.122 | 0.333 | |
| 4 week f/w | 11.09 ± 2.29 | 12.7 ± 2.79 | 14.76 ± 2.27 | 16.737 | 0.001 * | A, B > C |
| 8 week f/w | 10.68 ± 2.36 | 12.46 ± 2.74 | 14.52 ± 2.41 | 16.769 | 0.001 * | A, B > C |
| 12 week f/w | 10.34 ± 2.3 | 12.31 ± 2.63 | 14.47 ± 2.27 | 24.661 | 0.001 * | A, B > C |
| Time × Group | 4.394 | 0.001 * | ||||
| 6MWT | ||||||
| Baseline | 285.54 ± 98.57 | 244.54 ± 93.71 | 240.31 ± 51.72 | 1.568 | 0.218 | |
| 4 week f/w | 341.81 ± 109.11 | 295.55 ± 86.63 * | 245.43 ± 50.22 | 9.994 | 0.001 * | A, B > C |
| 8 week f/w | 351.91 ± 100.6 | 289.1 ± 89.3 * | 247.62 ± 52.86 | 6.74 | 0.002 * | A, B > C |
| 12 week f/w | 346.67 ± 101.95 | 284.6 ± 87.04 * | 252.93 ± 51.9 * | 5.67 | 0.006 * | A > C |
| Time × Group | 4.209 | 0.001 * | ||||
| SLS | ||||||
| Baseline | 5.68 ± 2.51 | 7.37 ± 1.95 | 6.48 ± 2.93 | 2.312 | 0.109 | |
| 4 week f/w | 8.56 ± 3.16 | 8.08 ± 1.89 | 6.56 ± 2.94 | 14.374 | 0.001 * | A > B, C |
| 8 week f/w | 9.83 ± 3.57 | 8.15 ± 1.94 | 6.32 ± 2.94 | 11.817 | 0.001 * | A > B, C |
| 12 week f/w | 9.7 ± 3.82 | 7.85 ± 2.18 | 6.95 ± 2.93 | 7.837 | 0.001 * | A > B, C |
| Time × Group | 8.381 | 0.001 * |
SD, standard deviation; AST, alternative step test; FTSST, five time sit to stand test; TUG, time up and go test; 6MWT, six meter walk test; SLS, single leg stance. * p < 0.05.
Outcome scores for each group at baseline, post-treatment, 8 week follow-up, and 12 week follow-up: mean and standard deviation (gait analysis).
| Outcome Measure | Hip | Quadriceps | Control | F |
| Post Hoc |
|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | ||||
| Stride (cm) | ||||||
| Baseline | 87.94 ± 10.20 | 87.58 ± 13.45 | 85.37 ± 8.48 | 0.268 | 0.766 | |
| 4 week f/w | 94.85 ± 13.00 | 90.65 ± 10.37 | 85.82 ± 8.82 | 24.768 | 0.024 * | A > C |
| 8 week f/w | 97.59 ± 13.14 | 90.85 ± 10.29 | 86.15 ± 8.52 | 5.902 | 0.005 * | A > C |
| 12 week f/w | 97.24 ± 10.46 | 90.70 ± 10.24 | 87.16 ± 8.94 | 7.304 | 0.002 * | A > B,C |
| Time × Group | 1.730 | 0.122 | ||||
| Single-stance(%) | ||||||
| Baseline | 31.71 ± 3.03 | 31.98 ± 2.30 | 31.64 ± 2.40 | 0.086 | 0.918 | |
| 4 week f/w | 34.37 ± 3.21 | 32.67 ± 2.45 | 31.81 ± 2.48 | 10.225 | 0.001 * | A > B,C |
| 8 week f/w | 35.31 ± 3.78 | 32.44 ± 2.42 | 31.81 ± 2.58 | 12.574 | 0.001 * | A > B,C |
| 12 week f/w | 34.99 ± 3.36 | 32.60 ± 2.39 | 32.23 ± 2.31 | 12.155 | 0.001 * | A > B,C |
| Time × Group | 3.933 | 0.001 * | ||||
| Double-stance(%) | ||||||
| Baseline | 33.37 ± 2.41 | 32.74 ± 4.28 | 33.69 ± 3.68 | 0.343 | 0.711 | |
| 4 week f/w | 29.62 ± 3.61 | 31.76 ± 3.75 | 33.69 ± 3.38 | 12.702 | 0.001 * | A > B,C |
| 8 week f/w | 28.75 ± 4.32 | 31.88 ± 3.67 | 33.51 ± 3.22 | 11.999 | 0.001 * | A > B,C |
| 12 week f/w | 28.90 ± 3.53 | 31.98 ± 3.83 | 33.24 ± 3.14 | 14.983 | 0.001 * | A > B,C |
| Time × Group | 4.462 | 0.001 * | ||||
| Speed (m/s) | ||||||
| Baseline | 0.82 ± 0.12 | 0.82 ± 0.11 | 0.80 ± 0.10 | 0.257 | 0.774 | |
| 4 week f/w | 0.93 ± 0.11 | 0.93 ± 0.11 | 0.81 ± 0.09 | 10.619 | 0.001 * | A,B > C |
| 8 week f/w | 0.97 ± 0.11 | 0.96 ± 0.11 | 0.81 ± 0.09 | 18.006 | 0.001 * | A,B > C |
| 12 week f/w | 0.96 ± 0.11 | 0.98 ± 0.12 | 0.82 ± 0.09 | 14.179 | 0.001 * | A,B > C |
| Time × Group | 4.270 | 0.001 * | ||||
SD, standard deviation. * p < 0.05.